Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the company's business, including, without limitation: Cadence is largely dependent on the success of its only product candidate, Acetavance, and cannot be certain that this product candidate will receive regulatory approval or be successfully commercialized; clinical trial data may fail to adequately support the safety and efficacy of Acetavance, or the prevalence or severity of adverse side effects may be greater than anticipated, which could prevent or significantly delay its regulatory approval; if changes made in transferring the manufacturing process for Acetavance result in a lack of comparability between the commercial product and the material used in clinical trials, Cadence may be required to perform additional non-clinical or clinical studies, which would delay the approval of the NDA for Acetavance, increase costs and adversely affect the company's business; heightened scrutiny by the FDA in the process of approving new drugs could delay or limit the company's ability to obtain regulatory approval for Acetavance; Cadence may require substantial additional funding in order to obtain regulatory approval of Acetavance and, if approved, to successfully launch this product candidate, and the company may not be able to raise sufficient capital when needed, or at all, particularly in light of the recent, unprecedented volatility in the capital markets; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press releas
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
2. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... University of Wisconsin-Madison researchers led by stem-cell pioneer ... cultures under cleaner and better-defined lab conditions than ... journal Nature Biotechnology, could pave the way for ... because of animal-cell contamination. Growing stem cells in ...
... continues to make stem-cell advances , such as ... things aren't going so well elsewhere in the world: ... South Korean stem-cell researcher, fell from grace in just ... stem-cell research results. , ,Originally, the allegations against him ...
... the original story was based on an official summary that referred ... certain amendments. Under the law as enacted, the source code would ... analyzed in the case of a recount, but not open to ... it may have caused. , , Madison, Wis. ...
Cached Biology Technology:Stem-cell controversies slow progress 2Voting machine source code must be available for review 2
(Date:7/10/2014)... chronic inflammatory skin diseases psoriasis* and eczema** are similar ... to base their decision on which treatment should be ... tissue samples. A team of researchers at the Helmholtz ... have now analyzed the molecular processes that occur in ... them for the first time to gain a detailed ...
(Date:7/10/2014)... July 10, 2014Women in the West African nation ... family planning option. Sayana Press has the potential ... of the health system and in communities by ... contraceptivePfizer,s Depo-Provera (depot medroxyprogesterone acetate)with the BD Uniject ... of four African countries expected to begin introducing ...
(Date:7/9/2014)... that,s not why the Millennials are eating it, according to ... annual International Recognition Days convention July 10th in Milwaukee. , ... that are quick, easy to cook and that can help ... about any health benefits of Tofu," said lead Cornell researcher ... it,s quick to cook and it,s filling.", The study of ...
Breaking Biology News(10 mins):New diagnostic test to distinguish psoriasis from eczema 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3
... LA JOLLA, Calif., September 25 2013 A new ... called medulloblastoma has been developed by researchers at Sanford-Burnham ... cellsthe cells that are critical for maintaining tumor growthand ... are essential for tumor progression. The process destroys the ...
... how their meat is sourced, with animal welfare ... many purchases. Unfortunately, many widely-used livestock production methods ... from the University of Cambridge has identified what ... silvopastoral systems which include shrubs and trees with ...
... , Sept. 25, 2013   GenoVive , an innovator ... against the emerging "globesity" epidemic through its development of ... on each individual,s unique metabolism.  "Weight Loss Designed by ... to customize an all natural meal and exercise program ...
Cached Biology News:New approach to treating human brain cancer could lead to improved outcomes 2New approach to treating human brain cancer could lead to improved outcomes 3Sustainable livestock production is possible 2Sustainable livestock production is possible 3"GenoVive is changing the face of personalized health by continuing research efforts with Harvard." 2
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Phospho-FADD (Ser194) Antibody (Human Specific)...
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Biology Products: